Darren D O'rielly

List of Publications by Year
in descending order

40 papers	663 citations	567281 15 h-index	610901 24 g-index
40 all docs	40 docs citations	40 times ranked	1186 citing authors

#	Article	IF	Citations
1	A pathogenic deletion in Forkhead Box L1 (FOXL1) identifies the first otosclerosis (OTSC) gene. Human Genetics, 2022, 141, 965-979.	3.8	7
2	Mutational Landscape of Autism Spectrum Disorder Brain Tissue. Genes, 2022, 13, 207.	2.4	7
3	Autosomal dominant non-syndromic hearing loss maps to DFNA33 (13q34) and co-segregates with splice and frameshift variants in ATP11A, a phospholipid flippase gene. Human Genetics, 2022, 141, 431-444.	3.8	7
4	An Exploration of Physical and Phenotypic Characteristics of Bangladeshi Children with Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 2021, 51, 2392-2401.	2.7	6
5	Genetic Epidemiology of Complex Phenotypes. Methods in Molecular Biology, 2021, 2249, 335-367.	0.9	3
6	Whole exome sequencing uncovered highly penetrant recessive mutations for a spectrum of rare genetic pediatric diseases in Bangladesh. Npj Genomic Medicine, 2021, 6, 14.	3.8	8
7	Clinical and molecular significance of genetic loci associated with psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101691.	3.3	5
8	A dominant <i>RAD51C</i> pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect. Molecular Genetics & Genomic Medicine, 2020, 8, e1070.	1.2	6
9	Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. Scientific Reports, 2020, 10, 21703.	3.3	5
10	The genetic architecture of Stargardt macular dystrophy (STGD1): a longitudinal 40-year study in a genetic isolate. European Journal of Human Genetics, 2020, 28, 925-937.	2.8	10
11	Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV). Scientific Reports, 2020, 10, 4925.	3.3	20
12	Complexities in Genetics of Psoriatic Arthritis. Current Rheumatology Reports, 2020, 22, 10.	4.7	23
13	Novel Usher syndrome pathogenic variants identified in cases with hearing and vision loss. BMC Medical Genetics, 2019, 20, 68.	2.1	10
14	The Genetics of Psoriasis and Psoriatic Arthritis. Journal of Rheumatology, 2019, 95, 46-50.	2.0	38
15	A review of ustekinumab in the treatment of psoriatic arthritis. Immunotherapy, 2018, 10, 361-372.	2.0	15
16	Ustekinumab in psoriatic arthritis and related phenotypes. Therapeutic Advances in Chronic Disease, 2018, 9, 191-198.	2.5	10
17	Real-world Experience of Using <i>HLA-B*27</i> Tag-single-nucleotide Polymorphism Assay to Screen for Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 1712-1712.	2.0	2
18	A review of ixekizumab in the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2018, 14, 993-1002.	3.0	12

#	Article	IF	Citations
19	Expression and Metabolomic Profiling in Axial Spondyloarthritis. Current Rheumatology Reports, 2018, 20, 51.	4.7	5
20	A common variant in CLDN14 causes precipitous, prelingual sensorineural hearing loss in multiple families due to founder effect. Human Genetics, 2017, 136, 107-118.	3.8	14
21	High Accuracy and Significant Savings Using Tag-SNP Genotyping to Determine<i>HLA-B*27</i>Status. Journal of Rheumatology, 2017, 44, 962.2-963.	2.0	5
22	Ankylosing spondylitis: beyond genome-wide association studies. Current Opinion in Rheumatology, 2016, 28, 337-345.	4.3	22
23	Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 923-935.	3.3	17
24	Private rare deletions in <i>SEC16A</i> and <i>MAMDC4</i> may represent novel pathogenic variants in familial axial spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 772-779.	0.9	17
25	Integrated Genomics Identifies Convergence of Ankylosing Spondylitis with Global Immune Mediated Disease Pathways. Scientific Reports, 2015, 5, 10314.	3.3	20
26	Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 623-642.	1.9	50
27	Genetics of psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 673-685.	3.3	39
28	Powered for Success: Considerations for Using the Candidate Gene Approach in Rheumatic Diseases in the Post-genomics Era. Journal of Rheumatology, 2014, 41, 1573-1575.	2.0	1
29	UGT2B17 copy number gain in a large ankylosing spondylitis multiplex family. BMC Genetics, 2013, 14, 67.	2.7	19
30	Advances in the Genetics of Spondyloarthritis and Clinical Implications. Current Rheumatology Reports, 2013, 15, 347.	4.7	11
31	Genome-Wide Signatures of â€˜Rearrangement Hotspotsâ€™ within Segmental Duplications in Humans. PLoS ONE, 2011, 6, e28853.	2.5	14
32	Pharmacogenetics of psoriasis. Pharmacogenomics, 2011, 12, 87-101.	1.3	24
33	Extending the scope of diagnostic chromosome analysis: Detection of single gene defects using high-resolution SNP microarrays. Human Mutation, 2011, 32, 1500-1506.	2.5	41
34	Genetics of susceptibility and treatment response in psoriatic arthritis. Nature Reviews Rheumatology, 2011, 7, 718-732.	8.0	55
35	Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. Pharmacogenomics and Personalized Medicine, 2010, 3, 15.	0.7	8
36	Evaluation for Psoriatic Arthritis in Dermatology Clinics. Journal of Cutaneous Medicine and Surgery, 2009, 13, S88-S92.	1.2	2

#	Article	IF	Citations
37	Psoriatic arthritis: genetic susceptibility and pharmacogenetics. Pharmacogenomics, 2008, 9, 195-205.	1.3	13
38	Spinal Prostaglandins Facilitate Exaggerated A- and C-fiber-mediated Reflex Responses and Are Critical to the Development of Allodynia Early after L5-L6 Spinal Nerve Ligation. Anesthesiology, 2007, 106, 795-805.	2.5	11
39	Increased Expression of Cyclooxygenase and Nitric Oxide Isoforms, and Exaggerated Sensitivity to Prostaglandin E2, in the Rat Lumbar Spinal Cord 3 Days after L5â€"L6 Spinal Nerve Ligation. Anesthesiology, 2006, 104, 328-337.	2.5	40
40	Inhibition of Spinal Prostaglandin Synthesis Early after L5/L6 Nerve Ligation Prevents the Development of Prostaglandin-dependent and Prostaglandin-independent Allodynia in the Rat. Anesthesiology, 2003, 99, 1180-1188.	2.5	41